Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea
NCT02156895 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 111
Last updated 2024-03-08
Summary
The objective of this study is to monitor the usage of INLYTA® in real practice, including the adverse events associated with INLYTA®.
Conditions
- Advanced Renal Cell Carcinoma
Interventions
- DRUG
-
based on Axitinib approval
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-07-17
- Primary Completion
- 2021-04-21
- Completion
- 2021-08-06
Countries
- South Korea
Study Locations
More Related Trials
-
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
NCT03695952 ·Status: ACTIVE_NOT_RECRUITING
-
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
NCT00328770 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
NCT04658147 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
NCT06138769 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
NCT02828124 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of Entecavir for Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
NCT04646928 ·Status: UNKNOWN
-
Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
NCT00703365 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
NCT01624285 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment
NCT03389126 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants
NCT05225207 ·Status: COMPLETED
-
A Study of PTS100 in Primary HCC Patients
NCT03447951 ·Status: RECRUITING ·Phase: PHASE2
-
First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment
NCT07297654 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
NCT03144661 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
NCT02528643 ·Status: COMPLETED ·Phase: PHASE2
-
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma
NCT05609695 ·Status: UNKNOWN
-
Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer
NCT00832689 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
NCT01246986 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
NCT05557838 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
NCT04246177 ·Status: COMPLETED ·Phase: PHASE3
-
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
NCT05010681 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers
NCT06611345 ·Status: RECRUITING ·Phase: NA
-
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
NCT06648057 ·Status: RECRUITING
-
Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma
NCT06365034 ·Status: RECRUITING
-
A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
NCT02178358 ·Status: COMPLETED ·Phase: PHASE2
-
Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
NCT02509507 ·Status: COMPLETED ·Phase: PHASE1/PHASE2